β-Arrestin-biased ligands at seven-transmembrane receptors

Trends in Pharmacological Sciences

Volumn 28, Issue 8, 2007, Pages 416-422

  Violin, Jonathan D ^a   Lefkowitz, Robert J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; BETA ARRESTIN; G PROTEIN COUPLED RECEPTOR; MU OPIATE RECEPTOR; PARATHYROID HORMONE RECEPTOR;

PRIORITY JOURNAL; REVIEW;

ALLOSTERIC REGULATION; ANIMALS; ARRESTINS; DRUG DESIGN; HUMANS; LIGANDS; MODELS, BIOLOGICAL; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 34447649922     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.06.006     Document Type: Review

References (48)

1. Ma P., and Zemmel R. Value of novelty?. Nat. Rev. Drug Discov. 1 (2002) 571-572
2. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 308 (2005) 512-517
3. Lefkowitz R.J., et al. New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol. Cell 24 (2006) 643-652
4. DeWire S.M., et al. Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69 (2007) 483-510
5. Benovic J.L., et al. beta-Adrenergic receptor kinase. Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. J. Biol. Chem. 263 (1988) 3893-3897
6. Lohse M.J., et al. beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 248 (1990) 1547-1550
7. Freedman N.J., and Lefkowitz R.J. Desensitization of G protein-coupled receptors. Recent Prog. Horm. Res. 51 (1996) 319-351
8. Zhang J., et al. Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. Receptors Channels 5 (1997) 193-199
9. Fisher A., et al. Selective signaling via unique M1 muscarinic agonists. Ann. N. Y. Acad. Sci. 695 (1993) 300-303
10. Gurwitz D., et al. Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands. Eur. J. Pharmacol. 267 (1994) 21-31
11. Karlin A. On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. J. Theor. Biol. 16 (1967) 306-320
12. Whistler J.L., and von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9914-9919
13. Lewis M.M., et al. Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J. Pharmacol. Exp. Ther. 286 (1998) 345-353
14. Kohout T.A., et al. Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J. Biol. Chem. 279 (2004) 23214-23222
15. Wei H., et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10782-10787
16. Blanpain C., et al. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol. Biol. Cell 13 (2002) 723-737
17. Gesty-Palmer D., et al. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281 (2006) 10856-10864
18. Holloway A.C., et al. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol. Pharmacol. 61 (2002) 768-777
19. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4 (2005) 919-927
20. Rochais F., et al. Real-time optical recording of beta(1)-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J. Clin. Invest. 117 (2007) 229-235
21. Swaminath G., et al. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J. Biol. Chem. 279 (2004) 686-691
22. Sakmar T.P., et al. Rhodopsin: insights from recent structural studies. Annu. Rev. Biophys. Biomol. Struct. 31 (2002) 443-484
23. Ahn S., et al. Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1740-1744
24. Shenoy S.K., et al. beta -arrestin-dependent, G protein-independent ERK1/2 activation by the beta 2 adrenergic receptor. J Biol Chem (2005)
25. Zhai P., et al. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J. Clin. Invest. 115 (2005) 3045-3056
26. Rajagopal K., et al. {beta}-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A (2006)
27. Sachpatzidis A., et al. Identification of allosteric peptide agonists of CXCR4. J. Biol. Chem. 278 (2003) 896-907
28. Bisello A., et al. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J. Biol. Chem. 277 (2002) 38524-38530
29. Keith D.E., et al. Morphine activates opioid receptors without causing their rapid internalization. J. Biol. Chem. 271 (1996) 19021-19024
30. Zhang J., et al. Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7157-7162
31. Bohn L.M., et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286 (1999) 2495-2498
32. Bruns I.R., et al. A potential novel strategy to separate therapeutic- and side-effects that are mediated via the same receptor: beta-arrestin2/G-protein coupling antagonists. J. Clin. Pharm. Ther. 31 (2006) 119-128
33. Groer C.E., et al. An Opioid Agonist that Does Not Induce Mu Opioid Receptor - Arrestin Interactions or Receptor Internalization. Mol Pharmacol (2006)
34. Raehal K.M., et al. Morphine side effects in beta-arrestin 2 knockout mice. J. Pharmacol. Exp. Ther. 314 (2005) 1195-1201
35. Bohn L.M., et al. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408 (2000) 720-723
36. Anborgh P.H., et al. Receptor/beta-arrestin complex formation and the differential trafficking and resensitization of beta2-adrenergic and angiotensin II type 1A receptors. Mol. Endocrinol. 14 (2000) 2040-2053
37. Violin J.D., et al. GRK and beta -arrestin mediated desensitization of the angiotensin II type 1A receptor elucidated by diacylgylcerol dynamics. J Biol Chem (2006)
38. Ahn S., et al. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J. Biol. Chem. 279 (2004) 35518-35525
39. Revankar C.M., et al. Arrestins block G protein-coupled receptor-mediated apoptosis. J. Biol. Chem. 279 (2004) 24578-24584
40. Rajagopal K., et al. When 7 transmembrane receptors are not G protein-coupled receptors. J. Clin. Invest. 115 (2005) 2971-2974
41. Gardella T.J., et al. Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology 137 (1996) 3936-3941
42. Rubin M.R., and Bilezikian J.P. Parathyroid hormone as an anabolic skeletal therapy. Drugs 65 (2005) 2481-2498
43. Kostenis E., et al. Techniques: promiscuous Galpha proteins in basic research and drug discovery. Trends Pharmacol. Sci. 26 (2005) 595-602
44. Barak L.S., et al. A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J. Biol. Chem. 272 (1997) 27497-27500
45. Bertrand L., et al. The BRET2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRS). J. Recept. Signal Transduct. Res. 22 (2002) 533-541
46. Vilardaga J.P., et al. Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat. Biotechnol. 21 (2003) 807-812
47. Gorse A.D. Diversity in medicinal chemistry space. Curr. Top. Med. Chem. 6 (2006) 3-18
48. McCammon J.A. Target flexibility in molecular recognition. Biochim. Biophys. Acta 1754 (2005) 221-224